On 5 October 2026, Huawei and Qualcomm announced a multi-year patent cross-licence covering 5G, compute, artificial intelligence (AI) and networking. Alongside the licence, Qualcomm has agreed to buy certain Huawei US patents. The Huawei-Qualcomm patent deal joins two companies that have been through a royalty dispute and US export restrictions, so it deserves a closer look.
The financial terms have not been disclosed. This article sets out what is confirmed and what is only reported, why each company is likely to have signed, and what may change for products, licensing, patent disputes and new technology.
What was announced
The joint announcement confirms four points:
- a multi-year cross-licence of the two patent portfolios in fields that include 5G, compute, AI and networking;
- the purchase by Qualcomm of certain Huawei US patents in compute, AI, networking and other technologies;
- support from both companies for licensing on fair, reasonable and non-discriminatory (FRAND) terms;
- a transaction that will close only after the necessary regulatory approvals.
Reuters adds Huawei’s own figures. Huawei expects the total value of its patent licensing agreements to pass USD 6.9 billion once the deal is completed, and it says its licensing business has generated positive revenue since 2021. Reuters also describes this as Huawei’s first patent licensing deal with Qualcomm that covers 5G.
Other points are reported but not agreed by both sides. Nikkei, as cited by TrendForce, reports that Qualcomm becomes the net payer for the first time. TrendForce also reports that Qualcomm will pay to use more than 680 Huawei patents, some of them registered in the US. Bloomberg, citing a Huawei spokesperson, reports that Qualcomm is licensing patents related to Huawei’s LogicFolding chip technology.
Qualcomm disputes two of these points. Anshel Sag of Moor Insights & Strategy writes that Qualcomm issued a second statement saying it is not a net payer and that claims linking the agreement to LogicFolding are inaccurate.
Until a regulatory filing gives numbers, the direction and the size of the payments should be treated as open.
How the two companies got here
| Date | Event |
|---|---|
| 2001 | Huawei makes its first licensing payment to Qualcomm |
| 2011 | Huawei receives its first licensing income, from Motorola |
| 2019 | The US places Huawei on its Entity List, which restricts sales of US technology to the company |
| July 2020 | The two companies settle a royalty dispute and sign a new long-term licence, which includes a grant-back of rights to certain Huawei patents. Qualcomm estimates about USD 1.8 billion in revenue from the settlement and from royalties for the first half of 2020 |
| May 2024 | The US revokes Qualcomm’s licence to export 4G and certain other chips to Huawei. Qualcomm says in its annual report that it expects no further product revenue from Huawei |
| Late 2024 | Huawei’s licence from Qualcomm expires. Qualcomm says in its next quarterly report that it is in discussions with Huawei |
| August 2026 | Huawei and HP announce a multi-year global cross-licence that includes a licence to HP for certain Huawei Wi-Fi patents |
| 5 October 2026 | The cross-licence and the patent purchase are announced |
Since 2001 Huawei has been known as the payer in this relationship, although the 2020 licence already gave Qualcomm rights to certain Huawei patents. Whatever the net balance is now, Qualcomm has agreed to buy patents from a company that used to pay it.
Why the deal was signed
Neither company has explained its reasons in detail. The motives below are an analysis of the public facts.
Huawei’s likely motives
Its earlier licence had lapsed. Huawei now sells phones built on its own Kirin chips. Those phones still use cellular standards on which Qualcomm holds standard essential patents (SEPs), and Qualcomm reported in early 2025 that Huawei’s licence had expired. A new agreement is likely to remove that exposure for several years.
It can earn from patents it can make little use of. Huawei files heavily in the US, with 3,482 US patents granted in 2025 according to Moor Insights, but trade restrictions leave it with very little product business there. Selling and licensing US patents turns a filing cost into income. Mr Sag makes the same point about the patents being bought.
It gains recognition as a licensor. Qualcomm runs the largest patent licensing business in the cellular industry by revenue. A deal in which Qualcomm takes a licence and buys patents is likely to support Huawei’s position with other companies it approaches. Huawei’s chief intellectual property officer, Alan Fan, said in the announcement that the agreement shows the value of Huawei’s innovations and also recognises Qualcomm’s foundational contributions to communication technology.
Qualcomm’s likely motives
It restores a licence with a large handset maker. Qualcomm can no longer sell chips to Huawei, and its annual report warns that its results could suffer if Huawei devices take market share from manufacturers that use Qualcomm chips. A licence is likely to give Qualcomm a contractual basis for royalties on Huawei devices, whichever chip is inside.
It gains freedom to operate outside handsets. Compute, AI and networking are the areas in which Qualcomm is expanding beyond phones. A cross-licence with one of the largest patent holders in those fields, together with ownership of some of its US patents, reduces a risk before those product lines grow.
It may help in China. Many of Qualcomm’s customers are Chinese handset makers. Mr Sag writes that the deal, if approved, may help Qualcomm in its relationship with the Chinese government, which scrutinises companies’ business dealings in China.
What the deal is expected to achieve
The first expected result is patent peace in the licensed fields for the term of the agreement. Each company should be able to design products with less concern about the other’s portfolio.
For Huawei, the deal adds proceeds from the patent sale and a reference licence. For Qualcomm, it adds licence coverage and a larger defensive portfolio in the US.
The deal does not change export controls. It also still needs approval. Nikkei, as cited by TrendForce, reports that its value is above the USD 133.9 million threshold for review by the US Federal Trade Commission.
The wider signal: patents as strategic infrastructure
Much of the industry commentary since the announcement goes beyond the two companies. Three views come up repeatedly.
The first is that patents are becoming strategic infrastructure and not only legal assets. Huawei spent heavily on research while trade restrictions limited what it could buy and where it could sell. It is now converting that research into recurring licensing income, which makes the company less dependent on any single product market.
The second view is that Chinese companies are placing more value on patents, and on the research behind them, than many of their American counterparts. That is an opinion, and patent counts alone do not prove it. The trend still deserves attention, because the company that owns the patents sets the terms of the next negotiation.
The third view concerns the wider market. A structured agreement between two rivals reduces the risk of patent disputes for the suppliers and customers of both. It is also said to give Huawei a firmer legal footing outside China. The larger signal is that companies separated by deep geopolitical tension can still find commercial value in a negotiated patent agreement.
What may change for the industry
Products
Little will change in the short term. Qualcomm still cannot supply chips to Huawei, and Huawei’s phones will continue to use Kirin processors. The change is in design freedom, because engineers on both sides should be able to use techniques covered by the other company’s licensed patents with less risk of a later dispute.
Licensing
Three changes are likely.
First, large portfolio owners will settle more often through cross-licences with a balancing payment. The balance depends on the relative strength of the two portfolios, and that strength is assessed patent by patent.
Second, the deal becomes a comparable licence. Other handset and equipment makers that negotiate with either company will ask how their own terms compare, and courts that set FRAND rates look at comparable licences.
Third, licences are moving beyond cellular SEPs. This deal covers AI, compute and networking, and the HP deal covered Wi-Fi. For patents that are not tied to a standard, infringement has to be shown product by product.
Patent infringement and disputes
The risk of litigation between Huawei and Qualcomm falls for the term of the agreement. The risk for others does not.
Once the purchase closes, the patents will belong to a US company that can assert them in US courts or use them defensively. Companies in compute, AI and networking should check which patents have changed hands once the assignments are recorded at the USPTO.
Huawei is also likely to keep approaching companies that use its technology without a licence. It has signed cross-licences with Ericsson, Oppo and vivo, and each new agreement makes the next request harder to refuse.
New technology
Two telecom companies have put AI and compute patents into a licence. This shows where both expect future value to lie.
Work on 6G standards has begun, and both companies are large contributors to cellular standards. A settled relationship gives them a cleaner start for the next round of SEP declarations.
The reports on LogicFolding remain disputed. If they are confirmed, a US chip designer will have licensed chip technology from a Chinese company. That would be a notable change in the direction in which chip technology is usually licensed.
What to watch next
- The regulatory approvals, and how long they take.
- Any Qualcomm filing that shows the financial effect.
- The USPTO assignment records for the purchased patents.
- Whether other companies sign licences with Huawei in the following months.
Where patent research fits
Deals like this are negotiated on evidence: which patents are essential to a standard, which claims read on which products, and which of the other side’s patents can be challenged. Synoptic IP is a patent research firm founded in 2013, and this evidence is part of our daily work. We prepare SEP essentiality claim charts, evidence-of-use claim charts and invalidity searches for patent owners, implementers and law firms preparing for licensing negotiations of this kind.
This article is commentary based on public reports as of 6 October 2026. The terms of the agreement are confidential, and nothing here is legal or investment advice.
Filed under